Thinking about the importance of a fast and accurate diagnosis of tuberculosis, DiagCor's GenoFlow DR-MTB has been CE marked. Currently more than 8 million cases of tuberculosis are known worldwide and nearly 1 million people die due to this infection each year.
This high mortality is strongly related to the failure in the treatment compliance. According to the WHO, drug-resistant Tuberculosis is virtually found in all countries which imposes a major obstacle in the run to control and treat this infection.
Failure to completely cure tuberculosis due to drug resistance, vastly increases the chances of disease out-spread.
The GenoFlow DR-MTB covers the major mutation points found in most of drug resistance cases related to isoniazid and rifampicin.
"Getting our DR-MTB kit CE marked puts us closer in the fight to eradicate this disease and contribute to the wellbeing of our community". Dr. Tam, CEO of DiagCor.
Headquartered in Hong Kong, DiagCor has been dedicated solely to molecular diagnostics (MDx) since 2006. The global leader in flow-through hybridization technology, the company offers a range of products, solutions and services related to RNA and DNA analysis. As well as providing MDx laboratory services to Asia Pacific practitioners, Diagcor develops and manufactures MDx products and solutions, and offers MDx medical translation services and MDx consulting.
DiagCor Life Science